Skip to main content
SpringerLink
Log in

Sibeprenlimab bei Patienten mit IgA-Nephropathie

Phase-II-Studie

Sibeprenlimab in patients with IgA nephropathy

Phase 2 trial

  • Für Sie gelesen
  • Published:
Die Nephrologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J (2021) Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int 100(4):753–779. https://doi.org/10.1016/j.kint.2021.05.015

    Article  PubMed  Google Scholar 

  2. Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sjöström CD, Umanath K, Langkilde AM, Heerspink HJL (2021) A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 100(1):215–224. https://doi.org/10.1016/j.kint.2021.03.033

    Article  CAS  PubMed  Google Scholar 

  3. Mathur M, Chan TM, Oh KH, Kooienga L, Zhuo M, Pinto CS, Chacko B (2023) A PRoliferation-Inducing Ligand (APRIL) in the pathogenesis of immunoglobulin A nephropathy: a review of the evidence. J Clin Med 12(21):6927. https://doi.org/10.3390/jcm12216927

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Yeo SC, Barratt J (2023) The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy. Clin Kidney J 16(Suppl 2):ii9–ii18. https://doi.org/10.1093/ckj/sfad200

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kiryluk K, Sanchez-Rodriguez E, Zhou XJ, Zanoni F, Liu L, Mladkova N, Khan A, Marasa M, Zhang JY, Balderes O, Sanna-Cherchi S, Bomback AS, Canetta PA, Appel GB, Radhakrishnan J, Trimarchi H, Sprangers B, Cattran DC, Reich H, Pei Y, Ravani P, Galesic K, Maixnerova D, Tesar V, Stengel B, Metzger M, Canaud G, Maillard N, Berthoux F, Berthelot L, Pillebout E, Monteiro R, Nelson R, Wyatt RJ, Smoyer W, Mahan J, Samhar AA, Hidalgo G, Quiroga A, Weng P, Sreedharan R, Selewski D, Davis K, Kallash M, Vasylyeva TL, Rheault M, Chishti A, Ranch D, Wenderfer SE, Samsonov D, Claes DJ, Akchurin O, Goumenos D, Stangou M, Nagy J, Kovacs T, Fiaccadori E, Amoroso A, Barlassina C, Cusi D, Del Vecchio L, Battaglia GG, Bodria M, Boer E, Bono L, Boscutti G, Caridi G, Lugani F, Ghiggeri G, Coppo R, Peruzzi L, Esposito V, Esposito C, Feriozzi S, Polci R, Frasca G, Galliani M, Garozzo M, Mitrotti A, Gesualdo L, Granata S, Zaza G, Londrino F, Magistroni R, Pisani I, Magnano A, Marcantoni C, Messa P, Mignani R, Pani A, Ponticelli C, Roccatello D, Salvadori M, Salvi E, Santoro D, Gembillo G, Savoldi S, Spotti D, Zamboli P, Izzi C, Alberici F, Delbarba E, Florczak M, Krata N, Mucha K, Pączek L, Niemczyk S, Moszczuk B, Pańczyk-Tomaszewska M, Mizerska-Wasiak M, Perkowska-Ptasińska A, Bączkowska T, Durlik M, Pawlaczyk K, Sikora P, Zaniew M, Kaminska D, Krajewska M, Kuzmiuk-Glembin I, Heleniak Z, Bullo-Piontecka B, Liberek T, Dębska-Slizien A, Hryszko T, Materna-Kiryluk A, Miklaszewska M, Szczepańska M, Dyga K, Machura E, Siniewicz-Luzeńczyk K, Pawlak-Bratkowska M, Tkaczyk M, Runowski D, Kwella N, Drożdż D, Habura I, Kronenberg F, Prikhodina L, van Heel D, Fontaine B, Cotsapas C, Wijmenga C, Franke A, Annese V, Gregersen PK, Parameswaran S, Weirauch M, Kottyan L, Harley JB, Suzuki H, Narita I, Goto S, Lee H, Kim DK, Kim YS, Park JH, Cho B, Choi M, Van Wijk A, Huerta A, Ars E, Ballarin J, Lundberg S, Vogt B, Mani LY, Caliskan Y, Barratt J, Abeygunaratne T, Kalra PA, Gale DP, Panzer U, Rauen T, Floege J, Schlosser P, Ekici AB, Eckardt KU, Chen N, Xie J, Lifton RP, Loos RJF, Kenny EE, Ionita-Laza I, Köttgen A, Julian BA, Novak J, Scolari F, Zhang H, Gharavi AG (2023) Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy. Nat Genet 55(7):1091–1105. https://doi.org/10.1038/s41588-023-01422-x

  6. Barratt J, Tumlin J, Suzuki Y, Kao A, Aydemir A, Pudota K, Jin H, Gühring H, Appel G (2022) Randomized phase II JANUS study of atacicept in patients with IgA nephropathy and persistent proteinuria. Kidney Int Rep 7(8):1831–1841. https://doi.org/10.1016/j.ekir.2022.05.017

    Article  PubMed  PubMed Central  Google Scholar 

  7. Lv J, Liu L, Hao C et al (2023) Randomized phase 2 trial of telitaci- cept in patients with IgA nephropathy with persistent pro teinuria. Kidney Int Rep 8:499–506. https://doi.org/10.1016/j.ekir.2022.12.014

    Article  PubMed  Google Scholar 

  8. Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U, Witzke O, Gross O, Vielhauer V, Mann JF, Hilgers RD, Floege J (2015) Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 373(23):2225–2236. https://doi.org/10.1056/NEJMoa1415463

    Article  CAS  PubMed  Google Scholar 

  9. Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao M, Barbour S, Jardine MJ, Reich HN, Cattran D, Glassock R, Levin A, Wheeler DC, Woodward M, Billot L, Stepien S, Rogers K, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Zhang H, Perkovic V (2022) The TESTING randomized clinical trial. JAMA 327(19):1888–1898. https://doi.org/10.1001/jama.2022.5368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J (2023) Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2‑year results from a randomised phase 3 trial. Lancet 402(10405):859–870. https://doi.org/10.1016/S0140-6736(23)01554-4 (Erratum in: Lancet. 2023 Sep 9;402(10405):850)

    Article  CAS  PubMed  Google Scholar 

  11. Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V (2023) Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2‑year results from a randomised, active-controlled, phase 3 trial. Lancet 402(10417):2077–2090. https://doi.org/10.1016/S0140-6736(23)02302-4

    Article  CAS  PubMed  Google Scholar 

  12. Floege J (2024) A new alternative: inhibiting complement activation in patients with IgA nephropathy. Kidney Int 105(1):28–30. https://doi.org/10.1016/j.kint.2023.10.012

    Article  CAS  PubMed  Google Scholar 

  13. Zhang H, Rizk DV, Perkovic V, Maes B, Kashihara N, Rovin B, Trimarchi H, Sprangers B, Meier M, Kollins D, Papachristofi O, Milojevic J, Junge G, Nidamarthy PK, Charney A, Barratt J (2024) Results of a randomized double-blind placebo-controlled phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int 105(1):189–199. https://doi.org/10.1016/j.kint.2023.09.027

    Article  CAS  PubMed  Google Scholar 

  14. Tam FWK, Tumlin J, Barratt J, Rovin BH, Roberts ISD, Roufosse C, Cook HT, Bhangal G, Brown AL, Busch M, Dudhiya F, Duliege AM, Fraser DJ, Gale DP, Huang CC, Lai PC, Lee M, Masuda ES, McAdoo SP, Rosenkranz AR, Sommerer C, Sunder-Plassmann G, Szeto CC, Tang SCW, Williamson DE, Willcocks L, Vielhauer V, Kim MJ, Todd L, Zayed H, Tong-Starksen S, Lafayette R (2023) Randomized trial on the effect of an oral spleen tyrosine kinase inhibitor in the treatment of IgA nephropathy. Kidney Int Rep 8(12):2546–2556. https://doi.org/10.1016/j.ekir.2023.09.024

    Article  PubMed  PubMed Central  Google Scholar 

Weiterführende Literatur

  1. Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, Sperati CJ, Villanueva R, Wu MJ, Wang D, Borodovsky A, Badri P, Yureneva E, Bhan I, Cattran D (2024) Phase 2 trial of cemdisiran in adult patients with IgA nephropathy: a randomized controlled trial. Clin J Am Soc Nephrol. https://doi.org/10.2215/CJN.0000000000000384

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nephrologie, Universitätsklinikum Heidelberg (Nierenzentrum Heidelberg), Im Neuenheimer Feld 162, 69120, Heidelberg, Deutschland

    Claudia Sommerer

Authors
  1. Claudia Sommerer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudia Sommerer.

Ethics declarations

Interessenkonflikt

C. Sommerer gibt an, dass kein Interessenkonflikt besteht.

Additional information

Redaktion

Thorsten Feldkamp, Rendsburg-Eckernförde

Jens Lutz, Bremen

Lutz T. Weber, Köln

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sommerer, C. Sibeprenlimab bei Patienten mit IgA-Nephropathie. Nephrologie (2024). https://doi.org/10.1007/s11560-024-00719-0

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11560-024-00719-0

Search

Navigation